Diabetes After Total Pancreatectomy
Metabolic Diseases
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Eli Lilly and CompanyINDIANAPOLIS, IN
1 programGlucagon receptor antagonist LY2409021N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Eli Lilly and CompanyGlucagon receptor antagonist LY2409021
Clinical Trials (1)
Total enrollment: 20 patients across 1 trials
Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism
Start: Apr 2016Est. completion: Jul 202120 patients
N/AUnknown
Related Jobs in Metabolic Diseases
Manager, Patient Safety and Pharmacovigilance Operations
Kailera Therapeutics
Waltham, Massachusetts
6h ago
Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV
Amgen
California - San Francisco, US
Yesterday
(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)
Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago
Computational Chemist
Topos Bio
San Francisco Office
2d ago
Associate Director, Legal Operations & Contracts Management
Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr
Team Lead Manufacturing (m/w/d) Blutzuckermonitoring (BGM) und Point-of-Care (POC) Produkte - befristet
Roche
Mannheim
5d ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space